A5000426248- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Blood Pressure and Hypertension Studies
- Healthcare Systems and Public Health
- Cardiac Health and Mental Health
- Cardiac Imaging and Diagnostics
- Climate Change and Health Impacts
- Cardiovascular Health and Disease Prevention
- Thermoregulation and physiological responses
- Chemotherapy-induced cardiotoxicity and mitigation
- Cardiovascular Disease and Adiposity
- Hormonal Regulation and Hypertension
- Heart Rate Variability and Autonomic Control
- Cardiac pacing and defibrillation studies
- Diabetes Treatment and Management
- Lipoproteins and Cardiovascular Health
- Cardiac, Anesthesia and Surgical Outcomes
- Human Health and Disease
- Acute Myocardial Infarction Research
- Coronary Interventions and Diagnostics
- Medication Adherence and Compliance
- Cardiac Valve Diseases and Treatments
- Sodium Intake and Health
- Pulmonary Hypertension Research and Treatments
- Neurological Disorders and Treatments
National Medical Research Center of Cardiology
2016-2025
St Bartholomew's Hospital
2022
British Heart Foundation
2022
University of Leeds
2022
Queen Mary University of London
2022
William Harvey Research Institute
2022
Research Medical Center
2021
Institute of Cardiology
2005-2019
Ministry of Health of the Russian Federation
2005-2018
Institute of Experimental Cardiology
2005-2017
Purpose The purpose of this analysis was to investigate trastuzumab-associated cardiac adverse effects in breast cancer patients after completion (neo)adjuvant chemotherapy with or without radiotherapy. Patients and Methods Herceptin Adjuvant (HERA) trial is a three-group, multicenter, open-label randomized that compared 1 2 years trastuzumab given once every 3 weeks observation HER-2–positive cancer. Only who radiotherapy had normal left ventricular ejection fraction (LVEF ≥ 55%) were...
Aim To study the etiology and dynamics of prevalence mortality CHF; to evaluate treatment coverage such patients in a representative sample European part Russian Federation for 20-year period. Material methods A followed up 2002 through 2017 (n=19 276); population Nizhny Novgorod region examined 1998 (n=1922). Results During observation period since 2002, incidence major CHF symptoms (tachycardia, edema, shortness breath, weakness) tended decrease while cardiovascular diseases has...
Aim To study true prevalence of atrial fibrillation (AF) in a representative sample from the European part Russian Federation; to describe characteristics patients with AF; and provide frequency anticoagulant treatment.Material methods Cross-sectional data EPOCH epidemiological (2017) were used. Data collected 8 constituent entities size was 11 453 people. The included all respondents who had given their consent for participation older than 10 years. Statistical tests performed R system...
Objective. To evaluate the efficacy and safety of transcatheter aortic valve implantation (TAVI) in patients with severe coronary artery (CA) lesions without prior myocardial revascularization. Material methods. A retrospective study included 270 who underwent TIA 2016-2021. In some (n=200, group 1), TAVI was performed after preliminary percutaneous intervention (PCI), other cases (n=70, 2) — PCI. Propensity score matching performed. Finally, we distinguished 2 groups by 68 patients. These...
The aim of the expert council "First star duo telmisartan and indapamide in Russian Federation", dedicated to introduction a new fixed-dose combination (modified-release tablets) into clinical practice was formulate an opinion on potential use novel treatment hypertensive patients.
Background: Patients having been treated for breast cancer (BC) are at increased risk of cardiovascular disease (CVD). Participation patients with high (CVR) in comprehensive cardiac rehabilitation programs seems to be a promising area prevention; however, present there is no understanding the scope need such Russia. Aim: To evaluate frequency CVDs and their factors, total CVR BC who have undergone cardiotoxic antitumor treatment determine development this patient category. Methods: This was...
The adult heart contains small populations of multipotent cardiac progenitor cells (CPC) that present a convenient and efficient resource for treatment myocardial infarction. Several clinical studies direct CPC delivery by injection have already been performed but showed low engraftment rate limited beneficial effects procedure. «Cell sheet» technology has developed to facilitate longer retention grafted show new directions cell-based therapy using this strategy. In study we hypothesized...
To perform a repeated epidemiological study of representative sample in the European part Russian Federation 2017 and to compare dynamics arterial hypertension (AH) prevalence with effectiveness blood pressure (BP) control population compared 1998, 2002, 2007.A was created 2002 re-examined 2007 2017. In pilot project performed for examining Nizhniy Novgorod region.During 19 years follow-up, AH increased from 35.5 43.3%. Te awareness treatment coverage reached 76.9 79.3%, respectively,...
Heart failure with preserved ejection fraction (HFpEF) is frequently complicated by pulmonary hypertension (PH). A vascular contribution could be considered as a substantial therapeutic target in HFpEF and PH combined pre- postcapillary (Cpc-PH).We enrolled 50 patients Cpc-PH who were determined echocardiography to have artery systolic pressure (PASP) > 40 mmHg, resistance 3 Wood units, and/or transpulmonary gradient 15 mmHg.The assigned the phosphodiesterase 5 (PDE5) inhibitor sildenafil...
Relevant aspects of the pathogenesis, diagnosis, And treatment heart failure with preserved LV EFThis review analyzes results studies recent decade that focus on epidemiology, mechanisms development, diagnostic methods, and treatments ejection fraction (HFpEF). As expected, prevalence HFpEF continues to increase due growing contribution comorbidities structure causes for chronic (CHF), such as arterial hypertension left ventricular hypertrophy, obesity, kidney disease, well ageing population...
Systemic inflammation and coronary microvascular endothelial dysfunction are essential pathophysiological factors in heart failure (HF) with preserved ejection fraction (HFpEF) that support the use of statins. The pleiotropic properties statins, such as anti-inflammatory, antihypertrophic, antifibrotic, antioxidant effects, generally accepted may be beneficial HF, especially HFpEF. Numerous observational clinical trials have consistently shown a prognostic effect statins patients HFpEF,...
Diagnosis of heart failure with preserved ejection fraction (HFpEF) is associated certain difficulties since many patients HFpEF have a slight left ventricular diastolic dysfunction and normal filling pressure at rest. improved by using transthoracic stress-echocardiography dosed exercise (or stress test), which allows detection increased during the exercise. The present expert consensus explains requirement for test in diagnosing from clinical pathophysiological standpoints; defines...
Disclaimer. The EAC Guidelines represent the views of EAC, and were produced after careful consideration scientific medical knowledge, evidence available at time their publication. is not responsible in event any contradiction, discrepancy, and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use healthcare therapeutic strategies. Health professionals are encouraged take fully into account when...
(1) Background: Chronic inflammation and fibrosis are key players in cardiac remodeling associated with left ventricular hypertrophy (LVH) heart failure a preserved ejection fraction (HFpEF). Monocytes T-helpers (Th) involved both pro-inflammatory fibrotic processes, while regulatory T-cells (Treg) could be considered to suppress chronic the hypertrophied myocardium. We aimed estimate relationship between frequencies of circulating CD4+ T-cell monocyte subpopulations variables (LV) diastolic...
Systemic inflammation and coronary microvascular endothelial dysfunction are essential pathophysiological factors in heart failure with preserved ejection fraction (HFpEF) that support the use of statins. The pleiotropic properties statins, such as anti-inflammatory, antihypertrophic, antifibrotic, antioxidant effects, generally accepted may be beneficial HF, especially HFpEF. Numerous observational clinical trials have consistently shown a prognostic effect statins patients HFpEF, while...
Heart failure withpreserved ejection fraction (HFpEF) is a severe disease with an often unfavorable outcome. The prevalence of HFpEF continues to increase, while effective treatment options remain elusive. All the medical strategies used toimprove outcome in heart reduced proved ineffective HFpEF, which was probably due different mechanisms ofdevelopment these two types and diversity phenotypes. According current paradigm development, chronic mild pro-inflammatory statecauses coronary...
The article discusses the problem of improving effectiveness treatment heart failure with preserved left ventricular ejection fraction (HFpEF). relative "failure" early studies renin-angiotensin-aldosterone system inhibitors was largely due to lack understanding that patients HFpEF represent a heterogeneous group various etiological factors and pathogenetic mechanisms disease. Therefore, so-called personalized approach should be used in these patients. This is based on identification clearly...
(1) Background: The structural and functional features of the natural history asymptomatic hypertensive left ventricular hypertrophy (LVH) are not clearly defined. (2) Objective: To determine changes in LVH, as well incidence predictors transition to different phenotypes heart failure (HF) after a long-term follow-up. (3) Methods: Based on assessment chart reviews, we retrospectively selected 350 patients with concentric LVH LV ejection fraction (EF) ≥ 50%. After median follow-up 8.1 years,...
The article focuses on current aspects of epidemiology, clinical picture, and diagnostics patients with chronic heart failure (CHF) associated preserved left ventricular (LV) systolic function. Heart LV ejection fraction (HFpEF) is shown to be prevalent in a population that accounts for more than half all CHF cases. group at risk HFpEF consists primarily older women arterial hypertension, type 2 diabetes mellitus, obesity, atrial fibrillation. presents algorithms diagnosis based classic...
The document focuses on key issues of diuretic therapy in CHF from the standpoint current views pathogenesis edema syndrome, its diagnosis, and characteristics using diuretics various clinical situations.